HIRONC

HIRONIC Co., Ltd has successfully concluded its participation in the world-renowned aesthetic medical device exhibition, IMCAS 2025, held in Paris, France, from January 30 to February 2. During the event, HIRONIC showcased its latest technological advancements, receiving significant attention from industry professionals as it aggressively pursued global market expansion with its flagship and new products.

IMCAS is an international platform that annually introduces innovative aesthetic medical devices. At this prestigious venue, HIRONIC unveiled the New DOUBLO 2.0, SILKRO, and its latest device, SYNERJET. The SYNERJET, in particular, garnered significant interest from global distributors and medical professionals as a next-generation device based on needle-free injection technology. It enables faster and more efficient treatments compared to conventional injection therapies. Currently, exclusive distribution agreements are under negotiation in key markets such as the United States and Russia, signaling rapid global market expansion. 

The New DOUBLO 2.0, incorporating a fusion of Microfocused Ultrasound (MFU) and Radiofrequency (RF) technologies, demonstrated superior clinical efficacy over existing treatment methods and has secured certifications in multiple countries, including Thailand and Brazil. During a live demonstration session at IMCAS, Dr. Thitikom Lim from Thailand shared insights into the Triple Firm Protocol utilizing the New DOUBLO 2.0, drawing keen interest from attendees.

Meanwhile, SILKRO, an RF microneedling device, also received high praise in the growing global Energy-Based Device (EBD) market. The steady increase in interest in SILKRO during the exhibition further underscores HIRONIC’s expanding global influence.

Additionally, during the exhibition, HIRONIC hosted the ‘Global VVIP Partner Meeting’ to strengthen its collaborative network. Key partners from various countries, including Brazil and Thailand, attended to discuss strategic cooperation, with some being recognized as Top Partners of the Year for their outstanding contributions.

A company representative stated, “IMCAS 2025 was an opportunity to confirm that our innovative technologies and products are highly competitive on the global stage.” They further emphasized, “With the exceptionally positive response to SYNERJET, we are highly optimistic about expanding into new markets and increasing sales.”